Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts

Por um escritor misterioso

Descrição

Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research describing ASDAS LDA achievement among patients treated with biologic DMARDs (bDMARD) is limited. The aim of this study was to describe disease activity and patient-reported outcome measures (PROMs) among patients […]
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Impact of Achieving ASDAS LDA on Disease Activity and Patient
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
PDF) Effectiveness of switching between TNF inhibitors in patients
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Disease Activity-Guided Stepwise Tapering but Not Discontinuation
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Impact of tapering targeted therapies (bDMARDs or JAKis) on the
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Effect of body mass index on treatment response of biologic
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Oral Abstracts - 2020 - International Journal of Rheumatic
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Canadian Rheumatology Association Meeting Quebec City Convention
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Expert Perspective: Management of the Psoriatic Arthritis Patient
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
POS0905 ACHIEVEMENT OF PARTIAL REMISSION AND INACTIVE DISEASE IN
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
PDF) Golimumab as the First-, Second-, or at Least Third-Line
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
Full article: POSTER PRESENTATIONS
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported  Outcome Measures Among Patients with Ankylosing Spondylitis Treated with  Biologic DMARDs - ACR Meeting Abstracts
PDF) Multi-biomarker disease activity score as a predictor of
de por adulto (o preço varia de acordo com o tamanho do grupo)